Gravidez molar

Hancock BW. Staging and classification of gestational trophoblastic disease. Clin Obstet Gynecol Best Pract Res. 2003 Dec;17(6):869-83. Resumo

Sebire NJ, Fisher RA, Foskett M, et al. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. BJOG. 2003 Jan;110(1):22-6. Resumo

Soper JT. Gestational trophoblastic disease. Obstet Gynecol. 2006 Jul;108(1):176-87. Resumo

Soper JT, Mutch DG, Schink JC. Diagnosis and treatment of gestational trophoblastic disease: ACOG Practice Bulletin No. 53. Gynecol Oncol. 2004 Jun;93(3):575-85. Resumo

1. Hancock BW. Staging and classification of gestational trophoblastic disease. Clin Obstet Gynecol Best Pract Res. 2003 Dec;17(6):869-83. Resumo

2. Smith HO. Gestational trophoblastic disease epidemiology and trends. Clin Obstet Gynecol. 2003 Sep;46(3):541-56. Resumo

3. Loukovaara M, Pukkala E, Lehtovirta P, et al. Epidemiology of hydatidiform mole in Finland, 1975 to 2001. Eur J Gynaecol Oncol. 2005;26(2):207-8. Resumo

4. Altieri A, Franceschi S, Ferlay J, et al. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol. 2003 Nov;4(11):670-8. Resumo

5. Kim SJ, Bae SN, Kim JH, et al. Epidemiology and time trends of gestational trophoblastic disease in Korea. Int J Gynaecol Obstet. 1998 Apr;60(suppl 1):S33-8. Resumo

6. Sebire NJ, Fisher RA, Foskett M, et al. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. BJOG. 2003 Jan;110(1):22-6. Resumo

7. Altman AD, Bentley B, Murray S, et al. Maternal age-related rates of gestational trophoblastic disease. Obstet Gynecol. 2008 Aug;112(2 Pt 1):244-50. Resumo

8. Di Cintio E, Parazzini F, Rosa C, et al. The epidemiology of gestational trophoblastic disease. Gen Diagn Pathol. 1997 Nov;143(2-3):103-8. Resumo

9. Davis JR, Surwit EA, Garay JP, et al. Sex assignment in gestational trophoblastic neoplasia. Am J Obstet Gynecol. 1984;148:722-725. Resumo

10. Szulman AE, Surti U. The syndromes of hydatidiform mole. I. Cytogenetic and morphologic correlations. Am J Obstet Gynecol. 1978 Jul 15;131(6):665-71. Resumo

11. Szulman AE, Surti U. The syndromes of hydatidiform mole. II. Morphologic evaluation of the complete and partial mole. Am J Obstet Gynecol. 1978 Sep 1;132(1):20-7. Resumo

12. Soper JT. Gestational trophoblastic disease. Obstet Gynecol. 2006 Jul;108(1):176-87. Resumo

13. Schlaerth JB, Morrow CP, Montz FJ, et al. Initial management of hydatidiform mole. Am J Obstet Gynecol. 1988 Jun;158(6 Pt 1):1299-306. Resumo

14. Berkowitz RS, Tuncer ZS, Bernstein MR, et al. Management of gestational trophoblastic diseases: subsequent pregnancy experience. Semin Oncol. 2000 Dec;27(6):678-85. Resumo

15. Lorigan PC, Sharma S, Bright N, et al. Characteristics of women with recurrent molar pregnancies. Gynecol Oncol. 2000 Sep;78(3 Pt 1):288-92. Resumo

16. Sand PK, Lurain JR, Brewer JI. Repeat gestational trophoblastic disease. Obstet Gynecol. 1984 Feb;63(2):140-4. Resumo

17. Berkowitz RS, Cramer DW, Bernstein MR, et al. Risk factors for complete molar pregnancy from a case-control study. Am J Obstet Gynecol. 1985 Aug 15;152(8):1016-20. Resumo

18. Soto-Wright V, Bernstein M, Goldstein DP, et al. The changing clinical presentation of complete molar pregnancy. Obstet Gynecol. 1995 Nov;86(5):775-9. Resumo

19. Soper JT, Mutch DG, Schink JC. Diagnosis and treatment of gestational trophoblastic disease: ACOG Practice Bulletin No. 53. Gynecol Oncol. 2004 Jun;93(3):575-85. Resumo

20. Norman RJ, Green-Thompson RW, Jialal I, et al. Hyperthyroidism in gestational trophoblastic neoplasia. Clin Endocrinol (Oxf). 1981 Oct;15(4):395-401. Resumo

21. Yamazaki K, Sato K, Shizume K, et al. Potent thyrotropic activity of human chorionic gonadotropin variants in terms of 125I incorporation and de novo synthesized thyroid hormone release in human thyroid follicles. J Clin Endocrinol Metab. 1995 Feb;80(2):473-9. Resumo

22. Coukos G, Makrigiannakis A, Chung J, et al. Complete hydatidiform mole. A disease with a changing profile. J Reprod Med. 1999 Aug;44(8):698-704. Resumo

23. Soper JT, Lewis JT, Hammond CB. Gestational trophoblastic disease. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and practice of gynecologic oncology. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1997:1039-77.

24. Kallen B. Hyperemesis during pregnancy and delivery outcome: a registry study. Eur J Obstet Gynecol Reprod Biol. 1987 Dec;26(4):291-302. Resumo

25. American College of Radiology. ACR-ACOG-AIUM-SRU practice parameter for the performance of obstetrical ultrasound. 2014 [internet publication].Texto completo

26. Twiggs LB, Morrow CP, Schlaerth JB. Acute pulmonary complications of molar pregnancy. Am J Obstet Gynecol. 1979 Sep 15;135(2):189-94. Resumo

27. Curry SL, Hammond CB, Tyrey L, et al. Hydatidiform mole: diagnosis, management, and long-term followup of 347 patients. Obstet Gynecol. 1975 Jan;45(1):1-8. Resumo

28. Tidy JA, Gillespie AM, Bright N, et al. Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecol Oncol. 2000 Sep;78(3 Pt 1):309-12. Resumo

29. Lao TT, Lee FH, Yeung SS. Repeat curettage after evacuation of hydatidiform mole. An appraisal. Acta Obstet Gynecol Scand. 1987;66(4):305-7. Resumo

30. Berkowitz RS, Im SS, Bernstein MR, et al. Gestational trophoblastic disease. Subsequent pregnancy outcome, including repeat molar pregnancy. J Reprod Med. 1998 Jan;43(1):81-6. Resumo

31. Montz FJ, Schlaerth JB, Morrow CP. The natural history of theca lutein cysts. Obstet Gynecol. 1988 Aug;72(2):247-51. Resumo

32. Medicines and Healthcare products Regulatory Agency. Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy. May 2019 [internet publication].Texto completo

33. Food and Drug Administration. Drug safety communication: FDA recommends against prolonged use of magnesium sulfate to stop pre-term labor due to bone changes in exposed babies. May 2013 [internet publication].Texto completo

34. Wang Q, Fu J, Hu L, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2017 Sep 11;(9):CD007289.Texto completo  Resumo

35. European Medicines Agency. European Medicines Agency recommends changes to the use of metoclopramide. Jul 2013 [internet publication].Texto completo

36. UK Teratology Information Service. Official response statement: use of ondansetron in the first trimester of pregnancy. Sep 2019 [internet publication].Texto completo

37. Huybrechts KF, Hernández-Díaz S, Straub L, et al. Association of maternal first-trimester ondansetron use with cardiac malformations and oral clefts in offspring. JAMA. 2018 Dec 18;320(23):2429-37.Texto completo  Resumo

38. Medicines and Healthcare products Regulatory Agency. Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy. Jan 2020 [internet publication].Texto completo

39. Asherman JG. Traumatic intra-uterine adhesions. J Obstet Gynaecol Br Emp. 1950 Dec;57(6):892-6. Resumo

40. Lurain JR, Brewer JI. Invasive mole. Semin Oncol. 1982 Jun;9(2):174-80. Resumo

41. Kohorn EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia. A progress report. J Reprod Med. 2002 Jun;47(6):445-50. Resumo

42. Mazur MT, Kurman RJ. Choriocarcinoma and placental site tumor. In: Szulman AE, Bauschman HJ, eds. Gestational trophoblastic disease. New York, NY: Springer-Verlag; 1987:45-68.